Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis

British Journal of Psychiatry

Volumn 206, Issue 2, 2015, Pages 93-100

  Hoskins, Mathew ^a   Pearce, Jennifer ^a   Bethell, Andrew ^a   Dankova, Liliya ^a   Barbui, Corrado ^b   Tol, Wietse A ^c   Van Ommeren, Mark ^d   De Jong, Joop ^e   Seedat, Soraya ^f   Chen, Hanhui ^g   Bisson, Jonathan I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BROFAROMINE; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VENLAFAXINE;

DRUG EFFICACY; EFFECT SIZE; HUMAN; META ANALYSIS; MONOTHERAPY; POSTTRAUMATIC STRESS DISORDER; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRESS DISORDERS, POST-TRAUMATIC;

HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84923011930     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.114.148551     Document Type: Review

References (82)

1. Steel Z, Chey T, Silove D, Marnane C, Bryant RA, van Ommeren M. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. JAMA 2009; 302: 537-49.
2. Karam EG, Andrews G, Bromet E, Petukhova M, Ruscio AM, Salamoun M, et al. The role of Criterion A2 in the DSM-IV diagnosis of post-traumatic stress disorder. Biol Psychiatry 2009; 68: 465-73.
3. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR). APA, 2000.
5. Brunello N, Davidson JR, Deahl M, Kessler RC, Mendlewicz J, Racagni G, et al. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 2001; 43: 150-62.
6. Ferry F, Bolton D, Bunting B, O'Neill S, Murphy S, Devine B. Economic Impact of Post Traumatic Stress in Northern Ireland. Northern Ireland Centre for Trauma and Transformation and University of Ulster Psychology Research Institute, 2010.
7. National Collaborating Centre for Mental Health. Post-traumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care. British Psychological Society/Royal College of Psychiatrists, 2005.
8. Australian Centre for Posttraumatic Mental Health. Australian Guidelines for the Treatment of Adults with Acute Stress Disorder and Posttraumatic Stress Disorder. ACPMH, 2007.
9. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. American Psychiatric Press, 2004.
10. Foa EB, Keane TM, Friedman MJ, Cohen J, eds. Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies (2 ed). Guilford, 2008.
11. Stein DJ, Zungu-Dirwayi N, Van der Linden GJ, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database of Systematic Reviews 2004; issue 2.
12. Institute of Medicine. Treatment of PTSD: An Assessment of the Evidence. National Academies Press, 2008.
13. Forbes D, Creamer M, Bisson JI, Cohen JA, Crow BE, Foa EB, et al. A guide to guidelines for the treatment of PTSD and related conditions. J Trauma Stress 2010; 23: 537-52.
14. Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S. Psychological treatments for chronic post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry 2007; 190: 97-104.
15. PRISMA Statement. 2009 (http://prisma-statement.org/statement.htm).
16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration, 2011.
17. Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 2006; 184: 21-5.
18. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6 month randomized controlled trial. Arch Gen Psychiatry 2006; 63: 1158-65.
19. Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007; 27: 85-8.
20. Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F. Divalproex in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol 2008; 281: 84-8.
21. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double blind comparison of sertraline for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 2007; 68: 711-20.
22. Wang H-H, Tan Q-R, Wang Z-Z, Wang H-N, Cheng C-G, Chen Y-C, et al. A randomised controlled study on prevention of posttraumatic stress disorder. J Clin Psychol Med 2009; 1: 1-3.
23. Martenyi F, Brown EB, Caldwell CD. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder. J Clin Psych 2007; 27: 166-70.
24. Matthew SJ, Vythilingam M, Murrough JW, Feder A, Luckenbaugh DA, Kinkead B, et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double blind, placebo controlled proof of concept trial. Euro Neuropsychopharmacol 2011; 21: 221-9.
25. Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, et al. Risperidone monotherapy for posttraumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006; 21: 275-80.
26. Panahi Y, Moghaddam BR, Sahebkar A, Sahebkar A, Nazari MA, Beiraghdar F, et al. A randomized, double blind, placebo controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychol Med 2011; 41: 2159-66.
27. Shalev AY, Ankri Y, Israeli-Shalev Y, Peleg T, Adessky R, Freedman S. Prevention of posttraumatic stress disorder by early treatment. Arch Gen Psychiatry 2011; 69: 166-76.
28. Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A. Reboxetine versus fluvoxamine in treatment of motor vehicle accident related posttraumatic stress disorder. J Clin Psychopharmacol 2006; 26: 152-6.
29. Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu SC, Capece JA, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double blind, placebo controlled trial. J Clin Psychiatry 2007; 68: 201-6.
30. Yeh MS, Mari JJ, Costa MC, Andreoli SB, Bressan RA, Mello MF. A double blind, randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther 2010; 175: 305-10.
31. Carey P, Suliman S, Ganesan K, Seedat S, Stein DJ. Olanzapine monotherapy in posttraumatic stress disorder: Efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 2012; 27: 386-91.
32. Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology 2012; 37: 996-1004.
33. Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2004; 161: 515-24.
34. Frommberger U, Stieglitz RD, Nyberg E, Richter H, Novelli FU, Angenendt J. Comparison between paroxetine and behaviour therapy in patients with posttraumatic stress disorder (PTSD): a pilot study. Int J Psychiatry Clin Practice 2004; 8: 19-23.
35. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003; 18: 1-8.
36. Kosten TR. Alexithymia as a predictor of treatment response in post-traumatic stress disorder. J Trauma Stress 1992; 5: 563-73.
37. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002; 159: 1777-9.
38. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2000; 283: 1837-44.
39. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001; 16: 197-203.
40. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry 1999; 175: 17-22.
41. Davidson JR, Kudler H, Smith R, Mahorney SL, Lipper S, Hammett E. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47: 259-66.
42. Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 1974-81.
43. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001; 58: 485-92.
44. Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S. Mirtzapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003; 53: 188-91.
45. Davidson JR. Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. Int Clin Psychopharmacol 2004; 19: 85-7.
46. Davis LL, Jewell ME, Ambrose S, Farley J, English B, Bartolucci A. A placebocontrolled study of nefazadone for the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol 2001; 24: 291-7.
47. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry 2000; 12: 101-5.
48. Katz RJ, Lott MH, Arbus P, Crocq L, Herlobsen P, Lingjaerde O. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety 1994; 1: 169-174.
49. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179: 366-70.
50. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158: 1982-8.
51. Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 2002; 181: 315-20.
52. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 2002; 63: 199-206.
53. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 860-8.
54. Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22: 190-5.
55. Kaplan Z, Amir M, Swartz M, Levine J. Inositol treatment of posttraumatic stress disorder. Anxiety 1996; 2: 51-2.
56. Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 2004; 19: 489-94.
57. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatr Res 1988; 24: 149-55.
58. Smajkic A, Weine S, Djuric-Bijedic Z, Boskailo E, Lewis J, Pavkovic I. Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. J Trauma Stress 2001; 14: 445-52.
59. Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 2004; 65: 1601-5.
60. Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick D, Keller T. A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of posttraumatic stress disorder. Psychopharmacology 1995; 122: 386-9.
61. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 2005; 29: 395-401.
62. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1991; 51: 236-8.
63. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45: 1226-9.
64. Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin S-H, Vermes D, et al. A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Depress Anxiety 2007; 24: 77-84.
65. McRae AL, Brady KT, Mellman TA, Sonn SC, Killeen TK, Timmerman MA. Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety 2004; 19: 190-6.
66. Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989; 146: 513-6.
67. Saygin MZ, Sungur MZ, Sabol EU, Cetinkaya P. Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bull Clin Psychopharmacol 2002; 12: 1-5.
68. Tucker P, Potter-Kimball R, Wyatt DB, Parker DE, Burgin C, Jones DE. Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Gen Psychopharmacol 2003; 37: 135-49.
69. Van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R. Fluoxetine treatment in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517-22.
70. Van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, et al. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry 2007; 68: 37-46.
71. Mooney P, Oakley J, Ferriter M, Travers R. Sertraline as a treatment for PTSD: a systematic review and meta-analysis. Irish J Psychol Med 2004; 21: 100-3.
72. Otto MW, Hinton D, Korbly NB, Chea A, Ba P, Gershuny BS, et al. Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther 2003; 41: 1271-6.
73. Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, et al. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 2006; 19: 625-38.
74. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 159: 1777-9.
75. Davidson JR, Connor KM, Hertzberg MA, Weisler RH, Wilson WH, Payne VM. Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol 2005; 25: 166-9.
76. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200: 97-106.
77. World Health Organization. Guidelines for the Management of Conditions Specifically Related to Stress. WHO, 2013.
78. Australian Centre for Posttraumatic Mental Health. Australian Guidelines for the Treatment of Acute Stress Disorder and Posttraumatic Stress Disorder. ACPMH, 2013.
79. Jonas DE, Cusack K, Forneris CA, Wilkins TM, Sonis J, Middleton JC, et al. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD). US Agency for Healthcare Research and Quality Comparative Effectiveness Review 92, 2013.
80. Watts BV, Schnurr PP, Mayo L, Young-Xu, Weeks WB, Friedman M. Metaanalysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry 2013; 74: e541-50.
81. Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007; 297: 468-70.
82. Davidson JRT, Connor KM, Hertzberg MA, Weisler RH, Wilson WH, Payne VM. Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol 2005; 25: 166-9